Medical Innovation Exchange

ContraFect tries to find path forward for MRSA drug despite ‘uninterpretable’ phase 3 results

https://www.fiercebiotech.com/biotech/contrafect-still-sees-promise-lead-candidate-despite-uninterpretable-phase-3-mrsa-results

Leave a Comment

Your email address will not be published. Required fields are marked *

Leave the field below empty!